VOMA enhances inflammation-impairing learning

Supplemental Table 1

ID / Q1 / Q3 / RT / DP / EP / CE / CXP
PGD2 / 351.1 / 233 / 6.20 / -60 / -10 / -18 / -19
d9 PGD2 / 360.1 / 280.2 / 6.15 / -55 / -10 / -26 / -19
PGE2 / 351.0 / 189.1 / 5.9 / -85 / -10 / -26 / -5
PGJ2 / 333 / 233.2 / 7.59 / -55 / -10 / -16 / -9
d9 PGE2 / 360.2 / 280.2 / 5.9 / -75 / -10 / -28 / -11
6 keto PGF1α / 369.1 / 163.1 / 4.2 / -120 / -10 / -38 / -3
d4 6 keto PGF1α / 373.1 / 167.2 / 4.2 / -120 / -10 / -38 / -11
IsoPVI / 353.2 / 115.0 / 5.5 / -55 / -10 / -30 / -5
8,12 IsoPVI / 353.1 / 115.0 / 6.6 / -85 / -10 / -30 / -7
d4IsoPVI / 357.2 / 115.0 / 5.5 / -125 / -10 / -30 / -9
IsoPIII / 353.2 / 193.0 / 5.2 / -105 / -10 / -36 / -3
IsoPIV / 353.0 / 126.9 / 5.0 / -75 / -10 / -32 / -11
d4-IsoP III / 357.2 / 197.0 / 5.2 / -125 / -10 / -36 / -7
PGF2α / 353.1 / 193 / 5.7 / -55 / -10 / -34 / -31
d4 PGF2α / 357.1 / 197 / 5.7 / -55 / -10 / -34 / -31
TXB2 / 369.1 / 169.1 / 5.2 / -75 / -10 / -28 / -5
11 dehydroTXB / 367.1 / 305.2 / 6.0 / -65 / -10 / -24 / -11
d4 TXB2 / 373.1 / 173.1 / 5.2 / -60 / -10 / -30 / -5

Table 1. MRM transitions for prostanoids and deuterated internal standards. The scheduled MRM transition valuesmonitored within a 1.5 min window.